United Immunity Acquires Carisma Therapeutics Assets to Advance In Vivo CAR-M Therapies for Solid Tumors and Fibrosis

 United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...

May 22, 2026 | Friday | News
Araceli Biosciences Launches Endeavor® Live Cell Platform for Ultra-High-Throughput Kinetic Imaging

Endeavor® Live Cell enables rapid kinetic imaging across large scale screening campaigns, generating the cellular data needed to support Lab-in-...

May 21, 2026 | Thursday | News
Lupin Receives U.S. FDA Tentative Approval for Generic Revefenacin Inhalation Solution

Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN)  announced that it has received...

May 20, 2026 | Wednesday | News
Full-Life Technologies Secures $150 Million Financing to Advance Radiotherapeutics Pipeline and Actinium-225 Manufacturing

Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, announced the completion of a US$150 million fi...

May 20, 2026 | Wednesday | News
Sanofi’s Phase 2 ElevAATe Data Show Efdoralprin Alfa Superior to Standard Augmentation Therapy in AATD

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...

May 20, 2026 | Wednesday | News
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® from Hansa Biopharma in €115 Million Deal

SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) announced that they have entered into an ...

May 20, 2026 | Wednesday | News
Harbour BioMed Showcases Best-in-Class Potential of Hu-mAtrIx™-Engineered LET003 in Obesity Treatment

Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...

May 19, 2026 | Tuesday | News
ImmunityBio and Japan BCG Laboratory Partner to Advance FDA Pathway for Tokyo-172 BCG in High-Grade NMIBC

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...

May 18, 2026 | Monday | News
CellDx-Tissue Receives US FDA Clearance, Strengthening Datar Cancer Genetics’ Global Precision Oncology and Biomarker Development Capabilities

Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...

May 18, 2026 | Monday | News
Valion Bio Secures First Commercial BioScan-NMR Deployment, Positioning Velocity Bioworks as a Pioneer in Advanced Diagnostic Innovation

First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Genera...

May 18, 2026 | Monday | News
Neurizon Therapeutics Receives HREC Approval for Phase 1 Study of NUZ-001 Oral Liquid Formulation in ALS

 Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...

May 15, 2026 | Friday | News
AOP Health and VRG Therapeutics Partner to Advance AI-Designed Kv1.3 Miniprotein Therapy for Autoimmune Diseases

- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, announced a strategic pa...

May 14, 2026 | Thursday | News
IBA Unveils AdaPTinsight XR to Advance Precision Imaging Across Proteus® Proton Therapy Systems

Proton therapy CBCT imaging solution across Proteus® Portfolio providing clarity and confidence in IGPT  IBA (Ion Beam Applications S.A., EURON...

May 14, 2026 | Thursday | News
Dark Horse Consulting Group and KunTuo Forge Strategic Alliance to Accelerate Biotherapeutic Clinical Trials in China

Dark Horse Consulting Group, a leading strategic and operational consulting enterprise in the field of biological therapy (hereinafter referred to as " DHC...

May 13, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close